Vitestro has raised 60 million euros in a Series B funding round to further develop and commercially scale its autonomous blood-drawing technology. The Utrecht-based company is working on the next generation of its Aletta Autonomous Robotic Phlebotomy Device, a system that can draw blood independently using ultrasound, robotics and artificial intelligence.
Aletta is designed for autonomic blood collection for diagnostic purposes. Using ultrasound, it locates suitable veins. A robotic arm then positions the needle very precisely to draw blood from the patient. The system can also switch blood collection tubes and apply a bandage after the procedure. This process should help address staff shortages, especially in routine blood sampling.
The investment will be used for product development, scaling up production and integrating the system with blood collection departments. The commercial rollout will begin in the Netherlands at hospitals participating in a clinical trial, followed by further introduction across Europe, with Denmark as the first international market. Vitestro is also working on regulatory approval in the US.
